Column Group IV GP, LP bought $38M of EIKN
owner at Eikon Therapeutics, Inc.. 2,117,760 shares at an average of $18.00, traded Feb 6, 2026, filed Feb 9, 2026.
Score components
- +12Role10% owner
- +25Trade size$38.1M at market
- +10Relative to holdingsHoldings up 74%
- +10Price context0% above the 52-week low
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -9.4%, 3m -31.6%, 6m -33.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-043320, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 6, 2026 | CConversion Common Stockindirect: By The Column Group IV, LP | +1,296,629 | - | - | 1,360,320 | Feb 9, 2026 |
| Feb 6, 2026 | CConversion Common Stockindirect: By The Column Group IV, LP | +1,403,568 | - | - | 2,763,888 | Feb 9, 2026 |
| Feb 6, 2026 | CConversion Common Stockindirect: By The Column Group IV, LP | +110,928 | - | - | 2,874,816 | Feb 9, 2026 |
| Feb 6, 2026 | CConversion Common Stockindirect: By The Column Group IV-A, LP | +44,249 | - | - | 47,601 | Feb 9, 2026 |
| Feb 6, 2026 | CConversion Common Stockindirect: By The Column Group IV-A, LP | +47,898 | - | - | 95,499 | Feb 9, 2026 |
| Feb 6, 2026 | CConversion Common Stockindirect: By The Column Group IV-A, LP | +3,785 | - | - | 99,284 | Feb 9, 2026 |
| Feb 6, 2026 | CConversion Common Stockindirect: By The Column Group Opportunity III, LP | +688,283 | - | - | 688,283 | Feb 9, 2026 |
| Feb 6, 2026 | POpen-market purchase Common Stockindirect: By The Column Group IV, LP | +1,437,323 | $18.00 | $26M | 4,312,139 | Feb 9, 2026 |
| Feb 6, 2026 | POpen-market purchase Common Stockindirect: By The Column Group IV-A, LP | +49,556 | $18.00 | $892k | 148,840 | Feb 9, 2026 |
| Feb 6, 2026 | POpen-market purchase Common Stockindirect: By The Column Group Opportunity III, LP | +630,881 | $18.00 | $11M | 1,319,164 | Feb 9, 2026 |
| Feb 6, 2026 | CConversion Series A Preferred Stockderivativeindirect: By The Column Group IV, LP | -9,670,000 | - | - | 0 | Feb 9, 2026 |
| Feb 6, 2026 | CConversion Series A Preferred Stockderivativeindirect: By The Column Group IV-A, LP | -330,000 | - | - | 0 | Feb 9, 2026 |
| Feb 6, 2026 | CConversion Series A-1 Preferred Stockderivativeindirect: By The Column Group IV, LP | -10,467,526 | - | - | 0 | Feb 9, 2026 |
| Feb 6, 2026 | CConversion Series A-1 Preferred Stockderivativeindirect: By The Column Group IV-A, LP | -357,216 | - | - | 0 | Feb 9, 2026 |
| Feb 6, 2026 | CConversion Series C-1 Preferred Stockderivativeindirect: By The Column Group IV, LP | -827,278 | - | - | 0 | Feb 9, 2026 |
| Feb 6, 2026 | CConversion Series C-1 Preferred Stockderivativeindirect: By The Column Group IV-A, LP | -28,229 | - | - | 0 | Feb 9, 2026 |
| Feb 6, 2026 | CConversion Series D Preferred Stockderivativeindirect: By The Column Group Opportunity III, LP | -5,133,076 | - | - | 0 | Feb 9, 2026 |
Related signals
Other insiders at Eikon Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | EIKNbuy Eikon Therapeutics, Inc. | Column Group IV GP, LP owner | $1.0M 89,200 shares | - | |
| 47Moderate | Eikon Therapeutics, Inc. | Foresite Capital Management IV, LLC owner | $1000k 55,555 shares | +4% | |
| 63Notable | Eikon Therapeutics, Inc. | Josh Wolfe director, owner | $5.0M 277,776 shares | - | |
| 63Notable | Eikon Therapeutics, Inc. | Josh Wolfe director, owner | $5.0M 277,776 shares | - | |
| 63Notable | Eikon Therapeutics, Inc. | Kenneth C Frazier director | $2.0M 111,111 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.